利润率下降很少是因为单次治疗成本上升。它下降是因为付款方组合转向基于价值的合同，而单次治疗成本从未计算过。 对医疗服务提供商来说，难点在于结构性的：已接受38,000人的 downside risk，却缺乏定价所需的分次治疗成本数据。因此任何可信的方案都必须同时掌握分次治疗成本和付款方组合，而这正是大多数内部分析止步的地方，因为两者存在于不同系统中。
利润率下降很少是因为单次治疗成本上升。它下降是因为付款方组合转向基于价值的合同，而单次治疗成本从未计算过。 对医疗服务提供商来说，难点在于结构性的：已接受38,000人的 downside risk，却缺乏定价所需的分次治疗成本数据。因此任何可信的方案都必须同时掌握分次治疗成本和付款方组合，而这正是大多数内部分析止步的地方，因为两者存在于不同系统中。
利润率下降有三种可能原因，应对方式完全相反。提供商成本上升而基于价值的费率未跟进。付款方组合转向按次支付更低的归属人合同。或者分次治疗成本因利用率提高、更多专科转诊以及合同内更长的管理时间而无形上升，而费率从未变化。
第三种最常见也最难察觉，因为它不会以单项费用增加的形式出现。它表现为来自38,000名归属人的相同收入，需要更多提供商时间和下游服务。混合利润率完全掩盖了这一点：两个分别贡献45%和15%的小组平均下来仍是可观的30%。
因此第一步几乎从来不是成本削减计划，而是按服务线、付款方合同和小组拆分利润率，直到平均值不再掩盖亏损合同。
这三者同时出现才是标志。单独一个通常指向其他问题。
✓ 归属人收入上升，而每名提供商的贡献保持不变。
✓ 基于价值合同的整体利润率看似可接受，却无人能说出任何单一合同的分次治疗成本。
✓ 新基于价值合同在季度末签署时未进行分次治疗成本建模。
通常会让情况更糟的做法。 对所有小组或支持人员进行统一规模缩减，这会从仍能覆盖分次治疗成本的小组中抽走产能。
It is for you if you run or finance a healthcare provider and revenue is up and profit is not. It is the situation where the numbers are available but nobody has put them in an order that produces a decision.
It is not for you if Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Below is an excerpt from a real run of this analysis on 一家医疗服务提供商. It is a sample profile rather than a customer, and it is engine output translated from English — this is the format you get, on your own numbers.
The subject is Cedar Ridge Health Partners, a sample company profile used for testing rather than a customer — 38,000 attributed lives under value-based contracts.
Excerpt from a real Percision run · Competitive Positioning · sample company profile
The move. Turn 38,000 downside-risk lives into a self-funding 36-month analytics platform via payer co-development.
The leak it closes. Settlement lag (6–9 months) and payer audit adjustments reduced via internal attribution engine
The assumption it rests on. Payer agrees to 5-year exclusivity and 15–25% platform margin split — the engine put the probability at 0.75.
| Investment required | $2.5–3.0M over 18 months |
| Expected return | 7.6–9.1× over three years on $2.5–3.0M investment |
| Revenue, year 1 | $0 (platform build phase) |
| Revenue, year 2 | $6.9–11.4M (first shared-savings settlement) |
| Revenue, year 3 | $13.7–22.8M (full run-rate) |
| Exit criteria | Terminate if payer refuses exclusivity by Month 6 OR if attribution accuracy <80% by Month 18 OR if shared-savings pool < $60M by end of contract year 2 |
This is one move out of a full analysis. Read a complete report — every page, no email required.
This question routes to 成本与利润率改善, one of 29 engagements the platform runs. For 医疗服务提供商 it works through cost per episode, payer mix, panel size and contribution per provider, then produces the sequence rather than a list of options — which move first, what it funds, and the observation that would say the sequence is wrong.
You watch the analysis get built before paying anything. 在此阅读完整报告 if you would rather see the depth first.
如果分析显示实际实现价格已低于所交付价值，则先提价——它出现在下一张发票上，无需新客户。如果问题是服务成本而非价格，则先降成本。同时做两者会无法判断哪一个起效。
不需要新系统。取前十大客户，分配明显的可变投入——支持时长、交付例外、定制工作、付款条款。排序通常在数字精确前就已清晰，而排序就是决策。
不是。有意用利润率换取份额是一种策略。问题是未经决定就滑入其中，而这几乎总是发生，因为每一次折扣都有理由，模式直到年底才显现。
Materially, yes. Downside risk has been accepted on 38,000 lives without the cost-per-episode data needed to price it — which changes both the diagnosis and the order of the fixes. The metrics that decide it here are cost per episode, payer mix, panel size, and an answer built on industry-general benchmarks will usually point at the wrong one first.
Less than most people expect. Your last twelve months of revenue and cost split the way you already split it, plus whatever you hold on cost per episode and payer mix. The analysis is explicit about what it is assuming where your data stops, which is more useful than waiting for numbers you may never have.
Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Describe the situation in your own words and we will tell you which analysis answers it — before you sign up for anything.
Describe my situation →Prefer to skip ahead? Go straight to the free diagnostic.
English · Español · Deutsch · Português · Français · Italiano · Nederlands · 日本語 · 한국어 · 中文 · Polski · Svenska · Türkçe · العربية · Tiếng Việt · ไทย · हिन्दी · עברית